Lisata Therapeutics agrees to Kuva Labs buyout at $4 per share

Kuva's wholly owned subsidiary Kuva Acquisition Corp launched the tender connection connected June 10, with the connection play acceptable to expire July 10, 2026.

Shareholders who tender their shares volition besides person 1 non-tradeable CVR entitling them to $1.25 per stock upon enrollment milestones successful a Phase 2a glioblastoma proceedings evaluating Lisata's pb campaigner certepetide, and a further $1.75 per stock if a New Drug Application for certepetide is filed oregon accepted for reappraisal by a regulatory authority.

Lisata's committee unanimously recommended that stockholders tender their shares. The merger statement contains nary financing condition, though Kuva disclosed it has not yet secured committed financing for the woody and intends to money the acquisition done a operation of debt, equity, oregon recognition facilities.

Following a palmy tender of a bulk of shares, Kuva volition get remaining shares done a second-step merger astatine the aforesaid consideration. The transaction is expected to adjacent successful the 3rd 4th of 2026.

Upon completion, Lisata volition beryllium delisted from the Nasdaq Capital Market